Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of delayed-release budesonide tablets (D23) in primary IgA nephropathy
CTR20253975Phase 2Active
- Sponsor
- Triastek
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of budesonide in IgA nephropathy (IgAN), sponsored by Triastek. Started Dec 2025; status: active.
02
Drugs
budesonide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20253975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253975.